Role of genes that modulate host immune responses in the immunogenicity and pathogenicity of vaccinia virus

Journal of Virology

Volumn 79, Issue 10, 2005, Pages 6554-6559

  Jackson, Shawn S ^a   Ilyinskii, Petr ^b,c   Philippon, Valérie ^b   Gritz, Linda ^b   Gómez Yafal, Alicia ^b   Zinnack, Kimberly ^b   Beaudry, Kristin R ^a   Manson, Kelledy H ^b   Lifton, Michelle A ^a   Kuroda, Marcelo J ^a   Letvin, Norman L ^a,c   Mazzara, Gail P ^b   Panicali, Dennis L ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Therion Biologics Corporation   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; VIRUS VECTOR;

ANIMAL EXPERIMENT; ARTICLE; B12R GENE; B13R GENE; B14R GENE; B16R GENE; B18R GENE; B19R GENE; B5R GENE; B8R GENE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GENE; GENE DELETION; GENE FUNCTION; HEALTH HAZARD; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; PATHOGENICITY; POXVIRUS; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS ATTENUATION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE;

AIDS VACCINES; ANIMALS; FEMALE; GENE DELETION; GENETIC VECTORS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; IMMUNIZATION; IMMUNIZATION, SECONDARY; LETHAL DOSE 50; MICE; MICE, INBRED BALB C; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRULENCE;

POXVIRIDAE; VACCINIA; VACCINIA VIRUS;

EID: 20944448671     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.10.6554-6559.2005     Document Type: Article

References (53)

1. Alcami, A., and G. L. Smith. 1992. A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell 71:153-167.
2. Alcami, A., and G. L. Smith. 1995. Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J. Virol. 69:4633-4639.
3. Altman, J. D., P. A. Moss, P. J. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94-96.
4. Amara, R. R., P. Nigam, S. Sharma, J. Liu, and V. Bostik. 2004. Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells. J. Virol. 78:3811-3816.
5. Antoine, G., F. Scheiflinger, F. Dorner, and F. G. Falkner. 1998. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244:365-396.
6. Banham, A. H., and G. L. Smith. 1993. Characterization of vaccinia virus gene B12R. J. Gen. Virol. 74:2807-2812.
7. Baxby, D. 1991. Safety of recombinant vaccinia vaccines. Lancet 337:913.
8. Belyakov, I. M., P. Earl, A. Dzutsev, V. A. Kuznetsov, M. Lemon, L. S. Wyatt, J. T. Snyder, J. D. Ahlers, G. Franchini, B. Moss, and J. A. Berzofsky. 2003. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl. Acad. Sci. USA 100:9458-9463.
9. Booss, J., and L. E. Davis. 2003. Smallpox and smallpox vaccination: neurological implications. Neurology 60:1241-1245.
10. Boursnell, M. E., I. J. Foulds, J. I. Campbell, and M. M. Binns. 1988. Non-essential genes in the vaccinia virus HindIII K fragment: a gene related to serine protease inhibitors and a gene related to the 37K vaccinia virus major envelope antigen. J. Gen. Virol. 69:2995-3003.
11. Colamonici, O. R., P. Domanski, S. M. Sweitzer, A. Larner, and R. M. Buller. 1995. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J. Biol. Chem. 270:15974-15978.
12. Combadiere, B., A. Boissonnas, G. Carcelain, E. Lefranc, A. Samri, F. Bricaire, P. Debre, and B. Autran. 2004. Distinct Time Effects of Vaccination on Long-Term Proliferative and IFN-{gamma}-producing T Cell Memory to Smallpox in Humans. J. Exp. Med. 199:1585-1593.
13. Crotty, S., P. Felgner, H. Davies, J. Glidewell, L. Villarreal, and R. Ahmed. 2003. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J. Immunol. 171:4969-4973.
14. Dallo, S., J. S. Maa, J. R. Rodriguez, D. Rodriguez, and M. Esteban. 1989. Humoral immune response elicited by highly attenuated variants of vaccinia virus and by an attenuated recombinant expressing HIV-1 envelope protein. Virology 173:323-329.
15. de Bruyn, G., A. J. Rossini, Y. L. Chiu, D. Holman, M. L. Elizaga, S. E. Frey, D. Burke, T. G. Evans, L. Corey, and M. C. Reefer. 2004. Safety profile of recombinant canarypox HIV vaccines. Vaccine 22:704-713.
16. DeFilippes, F. M. 1982. Restriction enzyme mapping of vaccinia virus DNA. J. Virol. 43:136-149.
17. Demkowicz, W. E., Jr., R. A. Littaua, J. Wang, and F. A. Ennis. 1996. Hum. cytotoxic T-cell memory: long-lived responses to vaccinia virus. J. Virol. 70:2627-2631.
18. Eichner, M. 2003. Analysis of historical data suggests long-lasting protective effects of smallpox vaccination. Am. J. Epidemiol. 158:717-723.
19. Engelstad, M., S. T. Howard, and G. L. Smith. 1992. A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope. Virology 188:801-810.
20. Engelstad, M., and G. L. Smith. 1993. The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence. Virology 194:627-637.
21. Gilbert, P. B., Y. L. Chiu, M. Allen, D. N. Lawrence, C. Chapdu, H. Israel, D. Holman, M. C. Keefer, M. Wolff, and S. E. Frey. 2003. Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials. Vaccine 21:2933-2947.
22. Gritz, L., A. Destree, N. Cormier, E. Day, V. Stallard, T. Caiazzo, G. Mazzara, and D. Panicali. 1990. Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env. J. Virol. 64:5948-5957.
23. Harrington, L. E., R. Most Rv, J. L. Whitton, and R. Ahmed. 2002. Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J. Virol. 76:3329-3337.
24. Isaacs, S. N., G. J. Kotwal, and B. Moss. 1992. Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc. Natl. Acad. Sci. USA 89:628-632.
25. Isaacs, S. N., E. J. Wolffe, L. G. Payne, and B. Moss. 1992. Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope. J. Virol. 66:7217-7224.
26. Jenkins, S., L. Gritz, C. H. Fedor, E. M. O'Neill, L. K. Cohen, and D. L. Panicali. 1991. Formation of lentivirus particles by mammalian cells infected with recombinant fowlpox virus. AIDS Res. Hum. Retroviruses. 7:991-998.
27. Kettle, S., N. W. Blake, K. M. Law, and G. L. Smith. 1995. Vaccinia virus serpins B13R (SPI-2) and B22R (SPI-1) encode M(r) 38.5 and 40K, intracellular polypeptides that do not affect virus virulence in a murine intranasal model. Virology 206:136-147.
28. Kotwal, G. J., and B. Moss. 1988. Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature 335:176-178.
29. Kotwal, G. J., and B. Moss. 1989. Vaccinia virus encodes two proteins that are structurally related to members of the plasma serine protease inhibitor superfamily. J. Virol. 63:600-606.
30. Kuroda, M. J., J. E. Schmitz, D. H. Barouch, A. Craiu, T. M. Allen, A. Sette, D. I. Watkins, M. A. Forman, and N. L. Letvin. 1998. Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. J. Exp. Med. 187:1373-1381.
31. Lane, J. M., and J. Goldstein. 2003. Evaluation of 21st-century risks of smallpox vaccination and policy options. Ann Intern Med. 138:488-493.
32. Legrand, F. A., P. H. Verardi, L. A. Jones, K. S. Chan, Y. Peng, and T. D. Yilma. 2004. Induction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes. J. Virol. 78:2770-2779.
33. Mazzara, G. P., A. Destree, and A. Mahr. 1993. Generation and analysis of vaccinia virus recombinants. Methods Enzymol. 217:557-581.
34. Meyer, H., G. Sutter, and A. Mayr. 1991. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72:1031-1038.
35. Moss, B. 1996. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. USA 93:11341-11348.
36. Moss, B., M. W. Carroll, L. S. Wyatt, J. R. Bennink, V. M. Hirsch, S. Goldstein, W. R. Elkins, T. R. Fuerst, J. D. Lifson, M. Piatak, N. P. Restifo, W. Overwijk, R. Chamberlain, S. A. Rosenberg, and G. Sutter. 1996. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv. Exp. Med Biol. 397:7-13.
37. Mossman, K., C. Upton, R. M. Buller, and G. McFadden. 1995. Species specificity of ectromelia virus and vaccinia virus interferon-gamma binding proteins. Virology 208:762-769.
38. Ourmanov, I., C. R. Brown, B. Moss, M. Carroll, L. Wyatt, L. Pletneva, S. Goldstein, D. Venzon, and V. M. Hirsch. 2000. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV. J. Virol. 74:2740-2751.
39. Paoletti, E. 1996. Applications of pox virus vectors to vaccination: an update. Proc. Natl. Acad. Sci. USA 93:11349-11353.
40. Ratner, L., W. Haseltine, R. Patarca, K. J. Livak, B. Starcich, S. F. Josephs, E. R. Doran, J. A. Rafalski, E. A. Whitehorn, K. Baumeister, et al. 1985. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313: 277-284.
41. Redfield, R. R., D. C. Wright, W. D. James, T. S. Jones, C. Brown, and D. S. Burke. 1987. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N. Engl. J. Med. 316:673-676.
42. Rosel, J. L., P. L. Earl, J. P. Weir, and B. Moss. 1986. Conserved TAAATG sequence at the transcriptional and translational initiation sites of vaccinia virus late genes deduced by structural and functional analysis of the HindIII H genome fragment. J. Virol. 60:436-449.
43. Rosenthal, S. R., M. Merchlinsky, C. Kleppinger, and K. L. Goldenthal. 2001. Developing new smallpox vaccines. Emerg. Infect. Dis. 7:920-926.
44. Santra, S., D. H. Barouch, S. S. Jackson, M. J. Kuroda, J. E. Schmitz, M. A. Lifton, A. H. Sharpe, and N. L. Letvin. 2000. Functional equivalency of B7-1 and B7-2 for costimulating plasmid DNA vaccine-elicited CTL responses. J. Immunol. 165:6791-6795.
45. Santra, S., D. H. Barouch, B. Korioth-Schmitz, C. I. Lord, G. R. Krivulka, F. Yu, M. H. Beddall, D. A. Gorgone, M. A Lifton, A. Miura, V. Philippon, K. Manson, P. D. Markham, J. Parrish, M. J. Kuroda, J. E. Schmitz, R. S. Gelman, J. W. Shiver, D. C. Montefiori, D. Panicali, and N. L. Letvin. 2004. Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. Proc. Natl. Acad. Sci. USA 101:11088-11093.
46. Shirai, M., K. Kurokohchi, C. D. Pendleton, T. Arichi, L. F. Boyd, H. Takahashi, D. H. Margulies, and J. A. Berzofsky. 1996. Reciprocal cytotoxic T lymphocyte cross-reactivity interactions between two major epitopes within HIV-1 gp160. J. Immunol. 157:4399-4411.
47. Smith, G. L., and Y. S. Chan. 1991. Two vaccinia virus proteins structurally related to the interleukin-1 receptor and the immunoglobulin superfamily. J. Gen. Virol. 72:511-518.
48. Smith, G. L., S. T. Howard, and Y. S. Chan. 1989. Vaccinia virus encodes a family of genes with homology to serine proteinase inhibitors. J. Gen. Virol. 70:2333-2343.
49. Spriggs, M. K., D. E. Hruby, C. R. Maliszewski, D. J. Pickup, J. E. Sims, R. M. Buller, and J. VanSlyke. 1992. Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein. Cell 71:145-152.
50. Symons, J. A., A. Alcami, and G. L. Smith. 1995. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 81:551-560.
51. Ueda, Y., S. Morikawa, and Y. Matsuura. 1990. Identification and nucleotide sequence of the gene encoding a surface antigen induced by vaccinia virus. Virology 177:588-594.
52. Verardi, P. H., L. A. Jones, F. H. Aziz, S. Ahmad, and T. D. Yilma. 2001. Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated In vivo without a concomitant reduction in immunogenicity. J. Virol. 75:11-18.
53. Zhou, J., L. Crawford, L. McLean, X. Y. Sun, M. Stanley, N. Almond, and G. L. Smith. 1990. Increased antibody responses to human papillomavirus type 16 L1 protein expressed by recombinant vaccinia virus lacking serine protease inhibitor genes. J. Gen. Virol. 71:2185-2190.